Cisco upgraded, PepsiCo downgraded: Wall Street's top analyst calls

HSBC upgraded Cisco (CSCO) to Buy with a $133 target, citing strong Q1 results. Wells Fargo upgraded Zimmer Biomet (ZBH) to Overweight with a $123 target. Goldman Sachs upgraded United Natural Foods (UNFI) to Buy with a $60 target. Morgan Stanley upgraded Nucor (NUE) to Overweight with a $310 target. Bernstein downgraded PepsiCo (PEP) to Underperform with a $128 target. JPMorgan downgraded Tyson Foods (TSN) to Neutral with a $65 target.

Original reporting
Published Nov 17, 2026, 2:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cisco upgraded, PepsiCo downgraded: Wall Street's top analyst calls — source image
Decision brief

The 30-second read

$CSCOBullishMed
01

Why it matters

The most actionable items are Cisco’s guidance raise paired with an upgrade, and PepsiCo’s downgrade tied to an expected earnings miss. Most other names are driven by analyst theses without additional new company data in the text.

02

Market read

Traders can use the Cisco and PepsiCo items for near-term sentiment and positioning, while the rest are lower-conviction thesis shifts from coverage changes.

03

What to watch

For several names, the article is thesis-only (valuation, regulatory path, product read-through). Traders should verify whether any of these notes coincide with upcoming earnings dates or concrete upcoming catalysts not mentioned here.

Relevance 6/10Novelty 4/10Timing: today’s analyst upgrade and downgrade notes

Background

The piece is a Wall Street analyst roundup featuring multiple rating upgrades/downgrades and price-target changes across industrials, healthcare, consumer, and retail, plus one explicit mention of Cisco raising fiscal 2027 guidance after strong fiscal Q1 results.

Company-level read

Ticker impact

$CSCOBullishHigh confidence
Context

HSBC upgraded Cisco to Buy and raised its price target after Cisco reported strong fiscal Q1 results and lifted fiscal 2027 earnings guidance.

Expected impact

Likely upward pressure as the market reprices Cisco’s earnings outlook and the Street’s stance.

Evidence & confidence

The article cites both an analyst rating/target change and a company-specific guidance raise, which are direct drivers for positioning.

$PEPBearishHigh confidence
Context

Bernstein downgraded PepsiCo to Underperform and cut its price target, saying PepsiCo is expected to miss earnings expectations over the next 12 months.

Expected impact

Likely downside pressure as investors price in a higher probability of underperformance versus expectations.

Evidence & confidence

The article provides a clear rating cut and a specific thesis about missing earnings expectations over the next year.

$ZBHBullishMedium confidence
Context

Wells Fargo upgraded Zimmer Biomet to Overweight and raised its price target, arguing Monogram should lift knee and worldwide growth.

Expected impact

Likely modest upside bias as the market reacts to improved growth outlook assumptions.

Evidence & confidence

The catalyst is a product thesis (Monogram) plus a target raise, but the article lacks new company data beyond the analyst note.

$MDTBullishLow confidence
Context

Piper Sandler upgraded Medtronic to Overweight from Neutral, signaling improved expectations for the stock.

Expected impact

Likely mild upward pressure as positioning shifts toward the upgraded view.

Evidence & confidence

The article states the upgrade but does not include a concrete new fundamental driver or numbers.

$UNFIBullishMedium confidence
Context

Goldman Sachs upgraded United Natural Foods to Buy and raised its price target, citing further runway for strong EBITDA growth.

Expected impact

Likely upward pressure as the market incorporates a stronger profitability path.

Evidence & confidence

The thesis is specific (EBITDA runway) and includes a target change, but it is still analyst-driven rather than a new company disclosure.

$NUEBullishMedium confidence
Context

Morgan Stanley upgraded Nucor to Overweight and raised its price target, increasing near-term steel price forecasts due to tight supply.

Expected impact

Likely upward pressure as investors reprice commodity-linked earnings sensitivity.

Evidence & confidence

The article ties the upgrade to updated steel price forecasts, but does not provide new Nucor-specific operational data.

$PRAXBullishMedium confidence
Context

Wells Fargo upgraded Praxis Precision to Overweight and sharply raised its price target after an investor day, citing improved positivity on ulixacaltamide D56 results.

Expected impact

Likely strong upside bias as the market reacts to improved trial-result interpretation and a higher target.

Evidence & confidence

The article references a specific trial result (D56) and a large target increase, but details are limited.

$TSNNeutralMedium confidence
Context

JPMorgan downgraded Tyson Foods to Neutral and raised its price target, saying the stock’s recovery better reflects fundamentals than the near-term outlook.

Expected impact

Likely limited upside or mild downside as the market discounts the downgrade’s caution.

Evidence & confidence

The article includes both a downgrade and a thesis about what the stock move already reflects, but no new Tyson datapoint.

Market effects

Broad retail and consumer coverage initiations plus selective downgrades/upgrades can shift relative performance within consumer discretionary and staples.

Primarily US-listed single-name positioning; limited direct cross-region impact implied.

Minimal, as the catalysts are analyst notes and company-specific guidance rather than global macro shocks.

Counterpoint

Analyst rating changes may be partially priced in quickly; without new company disclosures (beyond Cisco’s guidance raise), follow-through may be limited.

Key entities

  • Cisco

    Upgraded to Buy by HSBC with a raised price target after strong fiscal Q1 results and raised fiscal 2027 earnings guidance.

  • PepsiCo

    Downgraded to Underperform by Bernstein with a cut price target, citing expected earnings misses over the next 12 months.

Related articles

$PEPMed

Bernstein cuts PepsiCo to Underperform on North America pressure

Bernstein downgraded PepsiCo (PEP) to Underperform, cutting its price target to $128. The firm expects EPS to miss estimates due to North American business weakness, volume declines, and margin pressure from inflation and marketing costs. International growth may partially offset these issues, but significant investment is needed to revive the snacks business and compete in beverages. Bernstein forecasts EPS of $8.51, below the $8.91 consensus.

$PEPMed

Why Is PepsiCo Stock Falling 1.8% Following Bernstein Analyst Downgrade?

PepsiCo shares fell 1.8% in pre-market trading after Bernstein downgraded the stock to Underperform and cut its price target to $128, citing concerns over earnings outlook and investment needs. Analyst Cristian Rios expects earnings per share to miss forecasts due to North American sales pressure and spending requirements. PepsiCo shares were trading near $143.73, with a 52-week range of $123.47 to $171.48.

$PEPMed

Why is PepsiCo stock sliding today?

PepsiCo (PEP) shares fell 1.8% in pre-market trading after Bernstein downgraded the stock to 'Underperform' and cut its price target to $128, citing concerns about earnings and North American market challenges. Other analysts have also lowered their price targets, reflecting cautious sentiment. The stock traded at $143.73, well below its 52-week high of $171.48.

$CGONMed

Truist raises CG Oncology stock price target on trial results

Truist Securities raised its price target for CG Oncology (CGON) to $100 from $85, citing positive PIVOT-006 trial results. The stock is up 16.7% over the past week. Full data will be presented in December 2026, with FDA submissions expected in 2027. Analysts have revised earnings estimates upward, highlighting a multi-billion-dollar market opportunity.